Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Engineered antibodies act as targeted therapies in cancer treatment.

Literature DB >> 16391449

Engineered antibodies act as targeted therapies in cancer treatment.

Abstract

Over the last two decades cancer cure rates have not gone up as expected, and the effectiveness of chemotherapy has reached a plateau. This has prompted a search for targeted therapies with higher efficacy and lesser toxicities. Monoclonal antibodies against cancer cells offer targeted therapies with little or no toxicities against normal tissues. In this review we will discuss the concepts behind the development of monoclonal antibodies in cancer and their present status in the clinic. Specifically, we will discuss the clinical use of Rituximab (RituxanO), Trastuzumab (HerceptinO) and Bevacizumab (AvastinO) in various cancers and the key clinical trials that have led to their incorporation in cancer therapeutics.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2005 PMID： 16391449 DOI： 10.1007/BF02731669

Source DB: PubMed Journal: Indian J Pediatr ISSN： 0019-5456 Impact factor: 1.967

18 in total

1. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

Authors: J M Vose; B K Link; M L Grossbard; M Czuczman; A Grillo-Lopez; P Gilman; A Lowe; L A Kunkel; R I Fisher
Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544

2. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Authors: Michael J Keating; Ian Flinn; Vinay Jain; Jacques-Louis Binet; Peter Hillmen; John Byrd; Maher Albitar; Lee Brettman; Pedro Santabarbara; Bret Wacker; Kanti R Rai
Journal: Blood Date: 2002-05-15 Impact factor: 22.113

3. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.

Authors: Thomas E Witzig; Christine A White; Leo I Gordon; Gregory A Wiseman; Christos Emmanouilides; James L Murray; John Lister; Pratik S Multani
Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544

4. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Authors: Thomas E Witzig; Leo I Gordon; Fernando Cabanillas; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Brad L Pohlman; Nancy L Bartlett; Gregory A Wiseman; Norman Padre; Antonio J Grillo-López; Pratik Multani; Christine A White
Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544

Review 2. Immunotherapy for pediatric cancer.

Authors: Stephan A Grupp; Michael Verneris; Paul M Sondel; Laurence J N Cooper
Journal: Biol Blood Marrow Transplant Date: 2008-01 Impact factor: 5.742

2 in total

Engineered antibodies act as targeted therapies in cancer treatment.

1. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

2. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

3. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.

4. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Review 5. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.

Review 6. Alemtuzumab therapy in B-cell lymphoproliferative disorders.

Review 7. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

8. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Review 9. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.

Review 10. Clinical use of rituximab in haematological malignancies.

1. In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.

Review 2. Immunotherapy for pediatric cancer.